Renova Therapeutics | WebDisclosure

Basculer en Français

8295	Companies
114809	Keywords
55260	Articles
62422	Press releases

Home
Companies
Renova Therapeutics

BRIEF

published on 06/12/2024 at 15:05, 5 months 8 days ago

Renova Therapeutics Announces Potential Expansion of Gene Therapy Platform for Heart Failure, Diabetes and Related Conditions

Diabetes Clinical Trials Gene Therapy Renova Therapeutics Heart Failure
BRIEF

published on 06/12/2024 at 15:05, 5 months 8 days ago

Renova Therapeutics annonce l'expansion potentielle de sa plateforme de thérapie génique pour l'insuffisance cardiaque, le diabète et les affections associées

Essais Cliniques Thérapie Génique Rénova Thérapeutique Diabète Insuffisance Cardiaque
PRESS RELEASE

published on 06/12/2024 at 15:00, 5 months 8 days ago

Renova Therapeutics Announces Potential Expansion of Gene Therapy Platform for Heart Failure, Diabetes and Related Conditions
Renova Therapeutics announces exploration of new therapeutic opportunities expanding gene therapy use for diabetes and heart failure. Clinical trials and preclinical studies show promising results

Diabetes Clinical Trials Gene Therapy Renova Therapeutics Heart Failure
BRIEF

published on 05/09/2024 at 03:05, 6 months 12 days ago

Renova Therapeutics Prioritizes Gene Therapy Development for Heart Failure and Type 2 Diabetes

Clinical Trials Gene Therapy Renova Therapeutics Heart Failure Treatment Type 2 Diabetes Treatment
BRIEF

published on 05/09/2024 at 03:05, 6 months 12 days ago

Renova Therapeutics donne la priorité au développement de thérapies géniques pour l'insuffisance cardiaque et le diabète de type 2

Essais Cliniques Thérapie Génique Rénova Thérapeutique Traitement De L'insuffisance Cardiaque Traitement Du Diabète De Type 2
PRESS RELEASE

published on 05/09/2024 at 03:00, 6 months 12 days ago

Renova Therapeutics Announces Strategic Focus and Roadmap Prioritization for Its Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus
Renova Therapeutics prioritizes two primary regulatory pathways for launching pivotal human trials of gene therapies to treat heart failure and type 2 diabetes mellitus

Clinical Trials Gene Therapy Renova Therapeutics Heart Failure Type 2 Diabetes Mellitus

Accesswire

Published on 11/21/2024 at 09:00, 39 minutes ago

ProScore Announces Domestic Content Solution for Inflation Reduction Act Requirements
Published on 11/21/2024 at 00:35, 9 hours 4 minutes ago

Vision Marine Technologies Establishes a Strategic Hub for Electric Boat Sales, Rentals, and Distribution, Marking a Milestone at Dania Pointe’s Grand Opening of Aileron Residences
Published on 11/21/2024 at 00:25, 9 hours 14 minutes ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Published on 11/21/2024 at 00:00, 9 hours 39 minutes ago

Swiss Mining Institute Conference Presentation
Published on 11/20/2024 at 23:00, 10 hours 39 minutes ago

Rektron Group Inc. Announces Appointment of a New Director and Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 09:01, 38 minutes ago

Original-Research: Netfonds AG (von NuWays AG): Buy
Published on 11/21/2024 at 08:59, 39 minutes ago

Black Friday Savings: Kling AI Offers 50% Off and Free Feature Upgrades
Published on 11/21/2024 at 08:59, 39 minutes ago

Économies Black Friday : Kling AI propose 50 % de réduction et des mises à niveau gratuites des fonctionnalités
Published on 11/21/2024 at 08:15, 1 hour 24 minutes ago

EBIT increases to EUR 55.6 million. Equity (net asset value) increases by EUR 49.3 million to EUR 300.3 million, which corresponds to 70.14 euros per share. The equity ratio rises to 94.85%.
Published on 11/21/2024 at 08:09, 1 hour 29 minutes ago

KAP HOLDS ITS GROUND IN A DIFFICULT INDUSTRY ENVIRONMENT IN THE FIRST NINE MONTHS OF 2024

Les Echos

Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/21/2024 at 06:58, 2 hours 41 minutes ago

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Published on 11/20/2024 at 20:07, 13 hours 32 minutes ago

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Published on 11/20/2024 at 19:20, 14 hours 19 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

View all LES ECHOS COMFI WIRE